Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript

Benjamin Zeskind: Hey, Michael, thanks for thanks for the questions. And last, but certainly not least, so appreciate the question. And yeah, look, I mean, our phase 1 enrollment criteria is quite broad, right? It’s truly universal-RAS, any solid tumor patient with any mutation in KRAS, NRAS or HRAS is eligible to be screened. So we’re not requiring or specifying particular tumor type as part of the Phase 1. However, as you know, we’ve identified, what we believe are the most likely Phase 2a areas for dose expansion. And that’s based on the use of these humanized 3D tumor growth assays and the informatics that we described earlier. And so all our clinical investigators are familiar with those data and, in fact, we’ve chosen our clinical sites, in part based on their expertise with those types of cancer.

So, I think, you can expect €“ you might expect to see a bit a bit more of those in the trial. But again, we have €“ and I’ll hand over to Scott to comment. But again, we have very broad enrollment criteria to really kept a wide net. Scott, I don’t know if there’s anything you want to add there.

Scott Barrett: No. I think you covered it well. They’re all €“ the Phase 1 investigators are clinician scientists that we’re involved in our protocol developments and are very excited about the clinical proof-of-concept. And so, they’re basically actively looking to enrich for the tumor types that we built .

Michael Schmidt: Okay. Thank you.

Benjamin Zeskind: Great. Thanks, Michael.

Operator: Thank you. At this time, I would now like to turn the conference back over to Ben Zeskind for closing remarks.

Benjamin Zeskind: Great. Thank you, operator, and thanks everyone for the great questions, and to everyone who is listening on the call. In the coming weeks, we plan to attend the Cowen and Oppenheimer Healthcare Investor Conferences, and we welcome your requests for meetings at these events or directly through us. Feel free to reach out to Gilmartin, if you’d like to schedule some time. With that, I would like to thank all of you for participating in today’s call, and wish you a good evening.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.